By analyzing the MILE dataset (GSE13159, n = 2096), we found significant differences in B7‐H3 expression across five major hematological malignancies (CML, MDS, AML, CLL, and ALL) and healthy controls (ANOVA, p < 0.0001), with the highest level observed in AML (Figure 2A). This evidence concerns the gene CD276 and chronic myelogenous leukemia, BCR-ABL1 positive.